Genmab AS (OCSE:GMAB) Sale Of Property, Plant, Equipment : kr0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Sale Of Property, Plant, Equipment?

Genmab AS's sale of property, plant, equipment for the three months ended in Dec. 2024 was kr0 Mil. It means Genmab AS gained kr0 Mil from selling property, plant, and equipment. Genmab AS's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2024 was kr0 Mil.

Compared with last quarter (kr0 Mil in Sep. 2024 ), Genmab AS gained the same money from selling property, plant, and equipment in Dec. 2024 (kr0 Mil).

Genmab AS Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Genmab AS's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Sale Of Property, Plant, Equipment Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Sale Of Property, Plant, Equipment

Get a 7-Day Free Trial

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Sale Of Property, Plant, Equipment	Get a 7-Day Free Trial															-	-	-	-	-

Genmab AS Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

Genmab AS Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Genmab AS's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Sale Of Property, Plant, Equipment

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.